College of Pharmacy Dean Receives National Award
CINCINNATI - Daniel Acosta, PhD, dean for the University of Cincinnati College of Pharmacy, will receive the 2006 Award in Excellence of Pharmacology/Toxicology from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. The presentation will be made at the groups annual meeting April 1 in
The award is given annually to honorees who received a grant from PhRMA at the onset of their career and have gone on to distinguish themselves in research or administration.
I received my first grant from PhRMA at a critical point in my scientific career, says Dr. Acosta, a
He began his career as a research assistant at the
In 1996, Dr. Acosta became dean of UCs
Dr. Acostas own research has focused on the development of in vitro cell cultures as models for testing and mechanistic studies on drugs and toxicants. He was a key researcher in culturing cells that mimicked the normal tissues from which they were derived, which greatly reduced the need for experimental animal testing. The Society of Toxicology, the largest toxicology organization in the world, honored him for this work with the 2005 Enhancement of Animal Welfare Award.
In addition to being a pioneer in the development of alternative in vitro test methods, Dr. Acosta was successful in maintaining viable cultured cells from multiple sites, including liver, heart, kidney and nervous tissues.
Dr. Acosta has published over 125 original papers in peer-reviewed journals, authored 28 book chapters or reviews and edited three books.
Dr. Acosta is an inspirational leader to the faculty and students in the
Active in numerous scientific, professional and government organizations, Dr. Acosta is currently chairman of the FDA Scientific Advisory Board for the
Receiving this award is deeply humbling, says Dr. Acosta, especially since as an active administrator Im no longer directly involved in research. Im honored that the PhRMA believes my career can be considered one of excellence.
Tags
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
At least two weather patterns increase headaches, UC study suggests
June 4, 2026
University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.
UC researcher secures $3.3M grant to study microplastics’ impact on heart
June 2, 2026
The National Institute of Environmental Health Sciences awarded a $3.3M grant to University of Cincinnati researcher Hong‑Sheng Wang, PhD, to study how microplastics and nanoplastics affect cardiovascular health.